Nurix Therapeutics, Inc. (NRIX) stock
NRIXNasdaqPharmaceutical PreparationsFiscal year ends November 30
Financials through Q3 FY2026, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 13, 2026Score 15/3073% below fair value
$15.48−0.12 (-0.77%)
Close on Nov 13, 2026Market cap $1.69BP/E 6.7Yield 0.00%
Nurix Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Nurix Therapeutics's price to book ratio was 1.8× on Nov 11, 2026, against 3.7× a year earlier. Over the last 5 years it ranged from 1.2× to 6.6×, with a median of 2.2×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 1.8× | −2.1 |
| 2025 | Dec 31, 2025 | 3.9× | +0.6 |
| 2024 | Dec 31, 2024 | 3.4× | +1.2 |
| 2023 | Dec 29, 2023 | 2.1× | +0.6 |
| 2022 | Dec 30, 2022 | 1.5× | −1.9 |
| 2021 | Dec 31, 2021 | 3.4× | −0.7 |
| 2020 | Dec 31, 2020 | 4.2× | – |
See a number that looks wrong?